Maria Mar Hernandez Guillamon Senior Researcher, Neurovascular Research Lab, VHIR. Institutions of which they are part Main researcher Neurovascular Diseases Vall Hebron Institut de Recerca Twitter Email Maria Mar Hernandez Guillamon Twitter Email Institutions of which they are part Main researcher Neurovascular Diseases Vall Hebron Institut de Recerca Senior Researcher, Neurovascular Research Lab, VHIR.
Dr. Mar Hernández-Guillamon has dedicated her career to the study of cerebral amyloid angiopathy (CAA) and other pathologies associated with the deposition of amyloid-beta (Abeta). In 2013, she was awarded by Carlos III Spanish Health Institute with the Miguel Servet contract to establish the Cerebral Amyloidosis line of research at VHIR. Her group has positioned in forefront of the Abeta-pathologies field, studying the molecular mechanisms involved in the Abeta transport and metabolism using in vitro and in vivo models. Her lab has also dedicated to the clinical research and discovery of biomarkers associated with CAA and other cerebrovascular diseases. The translational research developed by Dr. Hernandez-Guillamon's group has allowed the achievement of important aims to date, as demonstrated by the scientific production obtained (h-index= 35, 80 publications, >3700 citations) and the continuous leadership of national and international projects.
Projects Role of Apolipoproteins (ApoE, ApoJ and ApoA-1) in Cerebral Amyloid Angiopathy: study of â-amyloid traffic across the blood brain barrier IP: Joan Montaner Villalonga Collaborators: Maria Mar Hernandez Guillamon, Laia Perez Lasarte Funding agency: Instituto de Salud Carlos III Funding: 202500 Reference: MS12/03259 Duration: 01/01/2013 - 31/12/2017 Estada al Dpt. de Patologia del New York University Medical School IP: Joan Montaner Villalonga Collaborators: Maria Mar Hernandez Guillamon Funding agency: Instituto de Salud Carlos III Funding: 1800 Reference: ESTSB-2010-01 Duration: 11/05/2010 - 14/07/2010 Mecanismos patogénicos de daño endotelial y neuronal (in vitro) producido por el suero de pacientes con ictus agudo y relación con los procesos oxidativos (in vivo) tras la isquemia cerebral IP: - Collaborators: Maria Mar Hernandez Guillamon Funding agency: Instituto de Salud Carlos III Funding: 113740 Reference: PI10/01605 Duration: 01/01/2011 - 31/12/2014 Beneficio de la Simvastatina en el tratamiento trombólico combinado del ictus en modelos de isquemia cerebral en rata IP: Maria Mar Hernandez Guillamon Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 126687 Reference: PI080481 Duration: 01/01/2009 - 31/12/2011 Pagination First page « Previous page ‹ … Page 5 Page 6 Current page 7 Page 8 Page 9 … Next page › Last page »
